ACADIA Pharmaceuticals Inc. vs Gartner Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Gartner Inc trades at $186.29 (market cap $11.83B). The key difference: Gartner Inc is far larger — about 2.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | IT | |
|---|---|---|
Market Cap | $5.07B | $11.83B |
Sector | Health | Technology |
52-Week High | $29.41 | $264.09 |
52-Week Low | $20.06 | $125.68 |
Enterprise Value | $4.19B | $13.57B |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →